Schedule and Program for the FDA-ASH Sickle Cell Disease (SCD) Clinical Endpoints Workshop
The FDA-ASH SCD Clinical Endpoints Workshop took place over the course of two days; below is an overview of each day.
-
October 17
7:00 a.m. Registration and Breakfast Available 8:00 a.m. Welcome and Introductions
Alexis A. Thompson, MD, MPH
ASH President
Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University8:15 a.m. Workshop Objectives and Regulatory Background
Ann Farrell, MD
Workshop Co-Chair
U.S. Food and Drug Administration8:30 a.m. Overview of SCD Endpoints: Then, Now, and Beyond
Julie Panepinto, MD, MSPH
Workshop Co-Chair
Medical College of Wisconsin9:00 a.m. Panel Session: Patient Reported Outcomes (PROs)
Patrick Carroll, MD
Panel Chair
Johns Hopkins University10:30 a.m. Coffee Break 10:45 a.m. Panel Session: Pain (non-PROs)
Deepika S. Darbari, MD
Panel Chair
Children’s National Medical Center12:15 p.m. Lunch 1:15 p.m. Panel Session: Brain
Allison King, MD, MPH
Panel Chair
Washington University in St. Louis2:45 p.m. Coffee Break 3:00 p.m. Panel Session: End Organ Considerations
Panel Chair
Jeffrey Lebensburger, DO
University of Alabama at Birmingham4:30 p.m. Workshop Day 1 Wrap-Up 5:00 p.m. Adjournment -
October 18
7:00 a.m. Registration and Breakfast Available 7:30 a.m. Panel Session: Biomarkers
Ankit Desai, MD
Panel Chair
Indiana University9:00 a.m. Coffee Break 9:15 a.m. Panel Session: Endpoints for How to Measure Cure
Mark Walters, MD
Panel Chair
Children’s Hospital of Oakland10:45 a.m. Coffee Break 11:00 a.m. Panel Session: Considerations of Endpoints for Low Resource Settings
Adetola A. Kassim, MD, MS
Panel Chair
Vanderbilt University12:15 p.m. Lunch 1:00 p.m. Patient Panel 1:50 p.m. Industry Panel 2:40 p.m. Research Organization Panel 3:30 p.m. Workshop Summary and Closing Remarks 4:00 p.m. Adjournment